<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640484</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-0706-PR-0026</org_study_id>
    <nct_id>NCT00640484</nct_id>
  </id_info>
  <brief_title>Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD</brief_title>
  <official_title>Evaluation of the Effect of 2 Weeks Treatment With CHF 4226 pMDI 2µg and 4µg, Given Once Daily in the Morning, on 24-Hour FEV1 in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiesi USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the dose of CHF 4226 (carmoterol) that should be
      given once a day to patients with COPD in order for the effect to last for 24 hours.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 AUC0-24 standardized by time</measure>
    <time_frame>on Day 15 (after 14 days of dosing)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1(L)</measure>
    <time_frame>30 min, 1, 2 ,3, 4, 6, 10, 12, 14, 16, 22, 23, and 24 hrs post dose at Visit 2 at all treatment periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>at the beginning and end of each of the four 14-day treatment periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>at the beginning and end of each of the four 14-day treatment periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 percent change</measure>
    <time_frame>30 min, 1, 2 ,3, 4, 6, 10, 12, 14, 16, 22, 23, and 24 hrs post dose at Visit 2 at all treatment periods</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 4226 (carmoterol) 2 μg once a day, in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 4226 (carmoterol) 4 μg once a day, in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo once a day, in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>salmeterol 50 μg twice daily, in the morning and in the evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmoterol (CHF 4226)</intervention_name>
    <description>carmoterol (CHF 4226) 2 μg once a day, in the morning
(1 puff of carmoterol 2 μg + 1 puff of placebo pMDI)</description>
    <arm_group_label>A</arm_group_label>
    <other_name>CHF 4226</other_name>
    <other_name>TA2005</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmoterol (CHF 4226)</intervention_name>
    <description>carmoterol (CHF 4226) 4 μg once a day, in the morning
(1 puff of carmoterol 2 µg + 1 puff of carmoterol 2µg)</description>
    <arm_group_label>B</arm_group_label>
    <other_name>CHF 4226</other_name>
    <other_name>TA2005</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo once a day, in the morning
(1 puff of placebo pMDI + 1 puff of placebo pMDI)</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol</intervention_name>
    <description>Salmeterol 50 μg twice daily, in the morning and in the evening
(1 blister of Serevent Diskus BID)</description>
    <arm_group_label>D</arm_group_label>
    <other_name>Serevent Diskus/Accuhaler</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed IRB approved Informed Consent form

          -  Male or non-pregnant female, 40 -75 years old, inclusive

          -  Current or past cigarette smoking history of at least 15 pack-years

          -  Clinical diagnosis of COPD in accordance with recommendations of the National Heart
             Lung and Blood Institute/World Health Organization (NHLBI/WHO) Global Initiative for
             Chronic Obstructive Lung Disease (GOLD)

          -  Patient meets following requirements after FEV1 albuterol reversibility test (i.e., 30
             minutes after 200μg (metered dose) albuterol MDI):

               -  FEV1/FVC &lt; 70%

               -  FEV1 is at least 0.9L

               -  FEV1 30% - 80%, inclusive, of patient's predicted normal value; ∆FEV1 &gt; 5% of
                  pre-albuterol value

               -  If ∆FEV1 &lt; 5% of pre-albuterol value, requirement must be met after retesting
                  during run-in period, at least 24 hours prior to Period 1/Visit 1.

        Exclusion Criteria:

          -  History of asthma

          -  Blood eosinophil count &gt; 500/microliters

          -  History of allergic rhinitis or atopy

          -  COPD exacerbation or lower respiratory tract infection within 8 weeks prior to
             screening, or during run-in period, that resulted in use of an antibiotic, or oral or
             parenteral corticosteroids

          -  Inhaled corticosteroid that has been initiated, or effective dose has been changed,
             within 4 weeks prior to screening or during run-in period

          -  Uncontrolled cardiovascular (e.g., uncontrolled hypertension), respiratory,
             hematologic, immunologic, renal, neurologic, hepatic, endocrine (e.g., uncontrolled
             diabetes mellitus) or other disease, or any condition that might, in Investigator's
             judgment, place patient at undue risk or potentially compromise study results or
             interpretation

          -  History of coronary artery disease, cerebrovascular disease, cardiac arrhythmias

          -  Lung cancer or history of lung cancer

          -  Active cancer or history of cancer with &lt; 5 years disease free survival time (with or
             without evidence of local recurrence or metastases). Localized basal cell carcinoma
             (without metastases) of skin is acceptable.

          -  Serum potassium value ≤ 3.5 mEq/L or &gt; 5.5mEq/L and/or fasting serum glucose value ≥
             140 mg/dL

          -  Abnormal QTcF interval value in Screening visit ECG test (i.e., &gt; 450 msec in males or
             &gt; 470 msec in females)

          -  Cor Pulmonale

          -  Long term oxygen therapy, i.e., &gt; 16 hours/24-hour period, every day, unless patient
             resides at elevation &gt; 4000ft

          -  Use of any of the following medications prior to Screening, without meeting specified
             minimum washout period:

               -  Long acting anti-cholinergic agent (i.e., tiotropium): 7 days

               -  Short acting anti-cholinergics: 8 hours

               -  Fixed combinations of β2-agonists and inhaled corticosteroids: 48 hours

               -  Fixed combinations of an anti-cholinergic and short acting β2-agonist: 8 hours

          -  Long-acting β2-agonists: 48 hours

          -  Short acting β2-agonists (other than those prescribed in the study): 6 hours

          -  Theophylline and other xanthines: 1 week

          -  Parenteral or oral corticosteroids: 1 month

          -  Patient has taken any non-permitted medication

          -  Patient has received live-attenuated virus vaccination within two weeks prior to
             screening or during run-in (inactivated Influenza vaccination is acceptable if given &gt;
             48 hours prior to Screening)

          -  Known intolerance/hypersensitivity to β2-adrenergic agonists, propellant
             gases/excipients

          -  Patient is pregnant or lactating female, or female at risk of pregnancy (i.e., not
             using adequate contraceptive method: surgical sterilization [e.g., bilateral tubal
             ligation], hormonal contraception [implantable, patch, oral], IUD, and double-barrier
             methods [any double combination of: male or female condom with spermicidal gel,
             diaphragm, sponge, cervical cap]).

          -  Patient is mentally or legally incapacitated

          -  Patient has participated in another investigational study within 30 days prior to
             screening

          -  Abuse of alcohol or other substances

          -  Patient does not maintain regular day/night, waking/sleeping cycles (e.g., night shift
             worker)

          -  Patient is potentially non-compliant or unable to perform required protocol outcome
             measurements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald P. Tashkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven E. Linberg, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Chiesi USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Horizon Clinical Research Associates, PLLC</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates, PA</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA David Geffen School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research - DeLand, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Medicine and Critical Care</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <zip>30106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sneeze, Wheeze &amp; Itch Associates, LLC</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Commonwealth BioMedical Research</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Horizons Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Southern Oregon, PC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma Allergy Associates</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reichman Associates</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Matera MG, Cazzola M. ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? Drugs. 2007;67(4):503-15. Review.</citation>
    <PMID>17352511</PMID>
  </reference>
  <reference>
    <citation>Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2005 Jul;14(7):775-83. Review.</citation>
    <PMID>16022567</PMID>
  </reference>
  <reference>
    <citation>Kikkawa H, Isogaya M, Nagao T, Kurose H. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. Mol Pharmacol. 1998 Jan;53(1):128-34.</citation>
    <PMID>9443940</PMID>
  </reference>
  <reference>
    <citation>Rossoni G, Manfredi B, Razzetti R, Civelli M, Bongrani S, Berti F. Positive interaction of the beta2-agonist CHF 4226.01 with budesonide in the control of bronchoconstriction induced by acetaldehyde in the guinea-pigs. Br J Pharmacol. 2005 Feb;144(3):422-9.</citation>
    <PMID>15655502</PMID>
  </reference>
  <reference>
    <citation>Rossoni G, Manfredi B, Razzetti R, Civelli M, Berti F. Positive interaction of the novel beta2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs. Pulm Pharmacol Ther. 2007;20(3):250-7. Epub 2006 Mar 14.</citation>
    <PMID>16533614</PMID>
  </reference>
  <reference>
    <citation>Voss HP, Shukrula S, Wu TS, Donnell D, Bast A. A functional beta-2 adrenoceptor-mediated chronotropic response in isolated guinea pig heart tissue: selectivity of the potent beta-2 adrenoceptor agonist TA 2005. J Pharmacol Exp Ther. 1994 Oct;271(1):386-9.</citation>
    <PMID>7965739</PMID>
  </reference>
  <reference>
    <citation>Kikkawa H, Kanno K, Ikezawa K. TA-2005, a novel, long-acting, and selective beta 2-adrenoceptor agonist: characterization of its in vivo bronchodilating action in guinea pigs and cats in comparison with other beta 2-agonists. Biol Pharm Bull. 1994 Aug;17(8):1047-52.</citation>
    <PMID>7820105</PMID>
  </reference>
  <reference>
    <citation>Voss HP, Donnell D, Bast A. Atypical molecular pharmacology of a new long-acting beta 2-adrenoceptor agonist, TA 2005. Eur J Pharmacol. 1992 Dec 1;227(4):403-9.</citation>
    <PMID>1359974</PMID>
  </reference>
  <reference>
    <citation>Kikkawa H, Naito K, Ikezawa K. Tracheal relaxing effects and beta 2-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea pig tissues. Jpn J Pharmacol. 1991 Oct;57(2):175-85.</citation>
    <PMID>1687479</PMID>
  </reference>
  <reference>
    <citation>Spadari-Bartfisch RC, Santos IN, Vanderlei LC, Marcondes FK. Pharmacological evidence for beta2-adrenoceptor in right atria from stressed female rats. Can J Physiol Pharmacol. 1999 Jun;77(6):432-40.</citation>
    <PMID>10537229</PMID>
  </reference>
  <reference>
    <citation>Matsukawa M, Takeda K, Shima H, Tagawa K, Banno K, Sato T. Enzyme-linked immunosorbent assay for TA-2005-glucuronide in human plasma. J Pharm Biomed Anal. 1998 Jun;17(2):245-54.</citation>
    <PMID>9638577</PMID>
  </reference>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2008</study_first_posted>
  <disposition_first_submitted>August 18, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 18, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 20, 2010</disposition_first_posted>
  <last_update_submitted>August 24, 2010</last_update_submitted>
  <last_update_submitted_qc>August 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Steven E. Linberg, PhD</name_title>
    <organization>Chiesi Pharmaceuticals Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

